Combining HRT and a GLP-1 for Menopause Weight: What the Evidence Shows

In January 2026, Mayo Clinic researchers reported that postmenopausal women taking tirzepatide (Zepbound, Mounjaro) lost more weight, on average, when they were also using systemic hormone therapy. The study looked back at medical records rather than assigning anyone to hormone therapy, so it shows an association, not that hormone therapy caused the extra weight loss.

If you are weighing both treatments, here is what that research found, what it cannot tell you, and what to raise with your provider. For the full study write-up, see our article on tirzepatide and HRT.

What the studies found

The tirzepatide study compared 120 postmenopausal women treated for at least 12 months: 40 using systemic menopausal hormone therapy and 80 who were not, matched on age, body mass index, age at menopause, type of menopause, earlier use of weight-loss medication, and diabetes. It was published in The Lancet Obstetrics, Gynaecology, & Women's Health in 2026.

• With hormone therapy: 19.2% average loss of total body weight at last follow-up
• Without hormone therapy: 14.0% average loss
• Difference: 5.2 percentage points, which Mayo Clinic's announcement described as about 35% more weight loss

An earlier Mayo study of semaglutide found a similar pattern: about 16% versus 12% average weight loss at 12 months, among 16 women using hormone therapy and 90 who were not.

What the studies cannot tell you

Because nobody was assigned to hormone therapy at random, the women who used it may have differed in ways the matching did not capture, such as activity, eating patterns, sleep or access to care. The tirzepatide study reported weight change; it does not show that hormone therapy protected muscle. And neither study tested what happens if a woman starts hormone therapy in order to lose more weight.

A 2026 expert review by the Spanish Menopause Society describes the menopause-specific evidence on these medicines as limited and largely observational, and a 2026 clinical review notes that hormone therapy is not indicated as a primary weight-loss treatment. Hormone therapy treats menopause symptoms; weight change on its own is not a reason to start it.

Why researchers think there might be a link

Estrogen affects where the body stores fat and how it handles blood sugar, so researchers have proposed metabolic explanations for the association. These are hypotheses. The studies above were not designed to test them.

When combining them might come up

Using both is a decision for you and your clinicians, based on your symptoms, your health history and the approved uses of each medicine. If menopause symptoms are the reason you are considering starting HRT, a menopause-trained clinician can go through both options with you. It may come up if:

• You have menopause symptoms that hormone therapy is used to treat
• You meet the criteria for a prescription weight-management medicine
• You have no contraindications to either treatment

If you already take both, make sure each prescriber knows about the other medicine. Tirzepatide slows stomach emptying, and its label tells women on birth control pills to switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose increase. That instruction is about contraception, not menopausal hormone therapy, but it is a reason to mention any hormone pills you take. Our guide to taking a GLP-1 and HRT together covers what the labels say.

Protecting muscle while you lose weight

Weight lost on these medicines can include muscle as well as fat, and appetite can drop far enough that protein falls short. Ask your clinician or a registered dietitian how much protein you need, and how to fit in resistance exercise that suits your health.

Side effects to watch

• Tirzepatide: the most common side effects are digestive, including nausea, diarrhea, vomiting and constipation. Most nausea, vomiting and diarrhea events happened while the dose was being increased and eased over time. Hair loss is also listed. The label warns about acute gallbladder disease and acute pancreatitis.
• Hormone therapy: side effects depend on the product, dose and route, and may include breast tenderness and irregular bleeding. Contraindications vary by product and commonly include breast cancer or a history of it, a current or past blood clot in the legs or lungs, and a current or past stroke or heart attack; your prescriber will review the specific regimen and your full history.

What the research hasn't answered yet

• Whether the same pattern holds for other GLP-1 medicines, including the newer oral options
• Whether the type of hormone therapy (patch, gel or pill) makes a difference
• What happens to weight, muscle and bone when women using both stop one or both treatments
• Whether a randomized trial would find the same difference

Until then, the honest summary is an association worth discussing with your provider, not a combination proven to work better.

This article is for educational purposes only and is not medical advice. GLP-1 and HRT decisions should involve a qualified provider who can review your complete health history and weigh appropriate benefits and risks.

Keep reading: GLP-1 medications in menopause · GLP-1 versus HRT for menopause weight · GLP-1 side effects in menopausal women